ZÜRICH--(BUSINESS WIRE)--CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505. CDR813 is a highly potent and selective TCE ...
Orca-Q, Orca Bio’s second investigational allogeneic T-cell immunotherapy, showed low rates of acute and chronic GvHD, infections and non-relapse mortality with and without GvHD prophylaxis Orca-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results